When people with heart disease add a drug called evolocumab to their cholesterol medicine (statin), their bad cholesterol drops by about 60% quickly and stays low for years, helping most of them reach very low cholesterol goals that are hard to hit with statins alone.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study looks at the same treatment (evolocumab plus statins) in the same group of people (adults with heart disease) and finds it lowers bad cholesterol a lot, just like the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Definitively quantify the average LDL-C reduction from evolocumab across all high-quality trials and assess heterogeneity by patient subgroup.
A Cochrane systematic review and meta-analysis of all double-blind, placebo-controlled RCTs of evolocumab in ASCVD patients, pooling mean LDL-C change at 12 and 48 weeks, stratified by baseline LDL-C, statin intensity, and diabetes status, with at least 5 trials and 10,000 total participants.
Establish causal effect of evolocumab on LDL-C reduction with high internal validity.
A double-blind, placebo-controlled RCT of 5,000 adults with ASCVD and LDL-C ≥1.8 mmol/L on maximally tolerated statin, randomized to evolocumab 140 mg Q2W vs placebo for 52 weeks, with LDL-C as primary endpoint measured centrally and blinded.
Confirm long-term durability and real-world effectiveness of LDL-C lowering.
A prospective, multicenter cohort study of 10,000 ASCVD patients initiating evolocumab in routine care, tracking LDL-C levels at 3, 12, and 24 months, with adjustment for statin adherence and background therapy.